0001209191-20-018121.txt : 20200311
0001209191-20-018121.hdr.sgml : 20200311
20200311165046
ACCESSION NUMBER: 0001209191-20-018121
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200219
FILED AS OF DATE: 20200311
DATE AS OF CHANGE: 20200311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abeliovich Asa
CENTRAL INDEX KEY: 0001778476
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38939
FILM NUMBER: 20705911
MAIL ADDRESS:
STREET 1: C/O PREVAIL THERAPEUTICS INC.
STREET 2: 430 EAST 29TH STREET, SUITE 940
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prevail Therapeutics Inc.
CENTRAL INDEX KEY: 0001714798
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET, SUITE 940
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 917-336-9310
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET, SUITE 940
CITY: NEW YORK
STATE: NY
ZIP: 10016
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-19
0
0001714798
Prevail Therapeutics Inc.
PRVL
0001778476
Abeliovich Asa
C/O PREVAIL THERAPEUTICS INC.
430 EAST 29TH STREET, SUITE 940
NEW YORK
NY
10016
1
1
1
0
President & CEO
Stock Option (Right to Buy)
16.91
2020-02-19
4
A
0
250000
0.00
A
2030-02-19
Common Stock
250000
250000
D
25% of the total number of shares underlying the option vest and become exercisable on February 19, 2021 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.
/s/ Alison Haggerty, Attorney-in-Fact
2020-03-11